COMPOSITIONS COMPRISING BLOCKERS OF L-DOPA RENAL CELL TRANSFER FOR THE TREATMENT OF PARKINSON'S DISEASE

摘要

A pharmaceutical composition for the treatment of Parkinson's disease comprises L-DOPA and at least one compound capable of blocking the L-DOPA renal cell outward transfer pathway; said blocking compound being chose from (a) a flavonoid phenyl benzopyran derivative; (b) a trans-stilbene derivative; or (c) phloretin [3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone]. The composition may also comprise an inhibitor of the enzyme amino acid decarboxylase (AADC), such a carbidopa or benserazide, and/or an inhibitor of the enzyme catechol-O-methyl transferase (COMT), such as entacapone or tolcapone. The composition is preferably administered in soli form and the L-DOPA may be administered simultaneously or sequentially with the L-DOPA renal cell outward transfer blocking compound.